Transforming drug discovery through network biology
We operate at the intersection between computational power and biological insight.
We have developed a proprietary network-driven computational platform to uncover new ways to fight disease and accelerate the discovery of novel and better treatments for patients.
Our technologies can be applied to any area of biology and are rapidly able to produce actionable outcomes.
I have extensive experience in the biotechnology sector and financial markets. Recent roles include CEO of Silence Therapeutics plc from 2012-2018 as well as a founder shareholder of Evolution Group, a U.K. based Investment Bank, from 2001-2008. I am an experienced investor in small companies and has held numerous declarable stakes in listed and private biotechnology and technology companies.
I have been instrumental in defining and developing the conceptual framework on which the network-driven drug discovery approach pioneered at e-therapeutics is based.
I moved from academia into biotech 13 years ago and have worked in both drug delivery and drug discovery. I am a clinician scientist with over 30 years’ experience in cell biology research and clinical medicine in a variety of roles including MRC Fellow, UCL Laboratory for Molecular Cell Biology, Visiting Fellow, The Jackson Laboratory USA, Lecturer & Medical Advisor UCL Institute of Ophthalmology, Hon Senior Lecturer UCL School of Pharmacy as well as senior clinical management positions. I gained a BSc (Biology & Computing), and a PhD in neuroscience from the University of London followed by postdoctoral work in Cambridge and medical studies at Oxford leading to the BM BCh in clinical medicine.
I am responsible for conceptualizing, defining, and implementing the network-driven approach to drug discovery pioneered at e-therapeutics.
I have over 30 years-experience in applying computational approaches to the study of complex biological problems. My PhD (Newcastle, UK) and Post-doctoral (The Neurosciences Institute at The Scripps Research Institute, US) studies were in computational neuroscience focused on how networks of the brain give rise to perception and function. After leaving academia, I moved into applied bioinformatics and software engineering at a number of biotech companies in the San Francisco Bay Area. My role at e-therapeutics merges my academic and industry experience, designing and developing the informatics to drive our network-biology based approach to drug discovery.
Outside of work I am a keen, if not particularly skilful, mountain biker.
My role involves the application of the ETX platform technology to internal and partnered drug discovery projects. I oversee the progress of projects with our CRO partners and biopharma collaborators.
By background I am a biochemist/cell biologist and have spent my career within the biopharma industry in both line and project management roles. I have been part of research teams in big/mid-size pharma companies, as well as smaller biotechs, and have worked with NCE and antibody discovery projects. Although I have probably spent most time in oncology, I have also worked in inflammation, anti-infectives and fibrosis.
Outside of work my interests lie with my family, my dog and my garden, although my wife would say that the dog always comes first.
I oversee our business and corporate development efforts, including securing and managing partnerships as well as maximising the value of our platform and the growth of the business. I work closely with the rest of the team to drive the execution of the corporate strategy.
My background is in advanced therapeutics and I have previously held senior BD and strategy positions at fast-paced organisations like Gyroscope Therapeutics and Silence Therapeutics. I received my PhD from Imperial College London, MRes in Biomedicine from UCL and BSc(Hons) in Biotechnology from UAB.
I love travelling, cooking and -the best part- eating. I also enjoy yoga and fitness and wish there were more hours in the day so I could learn to play a musical instrument!
I am responsible for the financial reporting and risk management frameworks of e-therapeutics. I also act as Company Secretary, the officer in charge of Health & Safety and Data Protection Officer.
I am a chartered accountant with over 10 years’ experience in finance, having trained at Blick Rothenberg in London and attained a first class BSc (Hons) in Biology and Business Management from Imperial College London.
My two young daughters take up most of my spare time and whist we’re enjoying finger painting and baking I’m looking forward to them being old enough to go on long country hikes and some more adventurous travel.
I look after the business development outreach and alliance management activities with bio-pharma.
I have over 15 years’ experience spanning research management, technology commercialisation, business development and alliance management roles in bio-pharma sector. I am trained as a scientist with a PhD in Medicinal Chemistry and attained an MBA with merit from Lancaster Business School. I have delivered numerous invited talks at global conferences, author of multiple patents and publications.
Outside work, I enjoy spending time with family, gardening and country walks.
I am a Principal Computational Biologist at e-therapeutics. I develop systems biology and network approaches to understand the underlying biology of drugs and diseases. I apply network-based computational methods to multiple drug discovery projects.
I have done my PhD in Computational Biology at Imperial College London, UK and a post-doc in the University of Cambridge, UK. My research was focused on the study of disease mechanisms in polygenic diseases, in particular in cancer. I was trained in biochemistry, biostatistics, systems biology and computational biology, and have authored several peer-reviewed scientific articles and book chapters.
Outside work, I like to spend most of my time with my family and friends. I also enjoy going to the gym and practice Cross-Fit, playing tennis and going to the cinema.
I am a computational biologist who is passionate about delivering high quality data and informative analyses to colleagues. My projects at e-therapeutics include the development as well as deployment of existing and bespoke computational approaches for multi-omics analyses and systems biology modelling (network reconstruction/inference and analysis).
I enjoy intrepid travels and discovering new cultures whenever possible. Otherwise, I spend most of my spare time exploring new recipes to share with friends and family, and afterwards convincing them to play one of my many board games for hours.
As a part of the informatics team, I am involved in developing and supporting drug discovery infrastructure and resources. This entails a wide range of works: from researching and implementing new analysis strategies, using computational and statistical techniques; to cleaning, analysing and visualising complex biological data; to test-driven code development and documentation.
I am trained as a bioinformatician and have a background in mathematical modelling and systems biology.
I love travelling, especially trekking to obscure destinations. Besides, I like running and also paddling around to explore English countryside.
As part of the informatics team, my role involves building new and proprietary tools to enhance capabilities of our in silico platform; but also extracting information from multi-scale genome datasets, with a strong emphasis in providing actionable insights for experimental validation.
I am computational biologist with a background in genetics (PhD in Genetics) and over 15 years' experience in academia and the biotech industry. I am specialised in the analysis of multi-scale genome datasets, statistics and computational modelling with a particular focus on the dynamics of biological systems.
I like to set up personal (non-scientific) projects which could take months or years. For example, the last couple of years I trained and run my first marathons. But I guess some of my recurring hobbies revolve around mountains and readings.
I am responsible for overseeing internal and external pre-clinical drug discovery programs through the utilisation of a network-driven approach to identify protein:protein interactions critical for disease modification and resolution. This is coupled with the identification and assessment of molecules capable of targeting and disrupting/enhancing those interactions.
I am an in vitro pharmacologist with over 18 years’ experience in the pharmaceuticals industry where I led and managed the delivery of pre-clinical drug discovery projects across multiple Neuroscience therapeutic areas. I gained my degree and PhD at the University of Bath and am a Member of the Royal Society of Biology.
In my spare time I am a full time dad, part-time dog walker, and occasional runner/swimmer/cyclist.
In my role at e-therapeutics, I utilize our platform to build and analyse biological network models of disease, and devise experiments for phenotypic screening of small molecule compounds. I have worked in a number of therapeutic areas, including neurodegenerative diseases and inflammation.
I have a PhD in Pharmacology, and an MSc in Applied Bioinformatics. Following postdoctoral positions at The National Institutes of Health in the USA and at the RVC, University of London, I have spent the last 14 years working in the biotech sector, mainly in drug discovery.
Outside of work, I have combined my love of sport and travel by becoming one of a small number of runners worldwide who have earned the Six Star Finisher medal for completing the six World Marathon Majors. My dream is to one day complete races on all seven continents! I am also a Leicester City FC season ticket holder, something which may have once been considered a curse rather than a pleasure, until recent miraculous exploits.
I graduated from Newcastle University with a first (hons) in computing science in 2005. I took a job at, what is now, e-Therapeutics as a programmer shortly after completing my degree. I’m am currently a Senior Scientific Programmer and my main responsibilities are centred around platform development.
As a Scientific Programmer my role is to attend to the development and maintenance requirements of the platform.
I joined the company after completing a PhD in self-organising multi-agent architectures for smart-grid cyber-security from Newcastle University, a MSc in Advanced Software Engineering from Durham university and a BSc in Computer Forensics from Northumbria university.
My spare time is mostly filled with local theatre, both directing and acting.
I deal with the day to day accounting at e-therapeutics, supporting the Finance Director and also the Executive Team.
I am AAT qualified with over 30 years’ experience in finance, including 20 years with Lloyds Bank.
My spare time is usually spent outdoors as much as possible, either running, cycling or walking - with the odd Clubbercise class thrown in!
Ali has extensive experience in the biotechnology sector and financial markets. Recent roles include CEO of Silence Therapeutics plc from 2012-2018 as well as a founder shareholder of Evolution Group, a U.K. based Investment Bank, from 2001-2008. Ali is an experienced investor in small companies and has held numerous declarable stakes in listed and private biotechnology and technology companies.
Trevor has over 40 years’ distinguished experience in the pharmaceutical and biotechnology industries as well as in academia. He is currently a Non-Executive Director of the life sciences investment company Arix Bioscience plc. He is also Visiting Professor at King’s College, London and holds honorary degrees and Gold Medals from seven universities. Previously, Trevor held significant roles in industry including Director of Allergan Inc. from 2005 to 2015 and R&D Director of The Wellcome Foundation from 1987 to 1994, where he was responsible for the development of AZT, Zovirax, Lamictal, Malarone and other medicines. Trevor has also held a number of advisory and regulatory roles including Director General of the Association of the British Pharmaceutical Industry (“ABPI”), Board member of the European Federation of Pharmaceutical Industry Associations (“EFPIA”) and the International Federation of Pharmaceutical Manufacturers Associations (“IFPMA”), a member of the UK Government regulatory agency, The Medicines Commission, a member of the UK Government Pharmaceutical Industry Ministerial Strategy Working Group on Pharmaceuticals, an adviser to the Cabinet Office on the Human Genome Project, a member of the Prime Minister’s Task Force on the Competitiveness of the Pharmaceutical Industry (“PICTF”) and Chair of the Government Advisory Group on Genetics Research. He joined the e-therapeutics Board in October 2015 and chairs the Remuneration Committee.
Michael was appointed to the Board of e-therapeutics plc as a Non-Executive Director in February 2020. He is also Chairman of the Audit Committee and a member of the Remuneration Committee. Michael is currently Chief Executive Officer of Sarossa Plc. In addition, he is Non-Executive Chairman of Adams Plc and Hardy Oil & Gas Plc and he is also a non-executive director of Blake Holdings Limited and ORA Limited. Michael has been a director of a number of other AIM quoted companies during the last ten years, including DeepMatter Group Plc, Tissue Regenix Group Plc, Nanoco Group Plc and Ceres Power Holdings Plc. He has a degree in Economics from Leeds University and is a member of the Institute of Chartered Accountants in England and Wales. His early career included working as an accountant and manager with PriceWaterhouse for 7 years in London and Abu Dhabi.